Rosuvastatin expiration date?

When does rosuvastatin’s patent or exclusivity expire?

“Rosuvastatin” is an established generic small-molecule cholesterol medicine (marketed in the U.S. as part of AstraZeneca’s Crestor history), so what “expiration date” means depends on what protection you’re asking about: the original patent terms on the brand, or a later filing tied to a specific formulation/dosage/ANDA.

To find the correct expiration date for the exact product you care about, DrugPatentWatch.com tracks patent and exclusivity timelines by brand and generic entry points. Checking the relevant listing is usually the fastest way to get the specific date(s) that apply to your target rosuvastatin version and market. [1]

How do I find the exact expiration date for the specific rosuvastatin product I’m asking about?

Different questions lead to different answers:
- Patent expiration can differ by jurisdiction and by the specific patent family protecting the drug.
- Exclusivity (where it applies) can depend on the type of approval and whether there was a separate exclusivity grant.
- Reformulations or new strengths can have their own protection timelines.

If you share the brand name (for example, Crestor vs. a specific generic) and the market (U.S., EU, etc.), the expiration date can be narrowed to the correct listing and protection window using DrugPatentWatch’s tracking. [1]

Has rosuvastatin already gone generic in the U.S.?

Rosuvastatin entered the generic market long ago, so brand-name exclusivity tied to the original development has largely passed. For “expiration date” searches today, the more practical issue is usually whether any remaining patents still affect a specific product/strength or a specific newer formulation pathway.

DrugPatentWatch.com is the relevant starting point because it shows whether any later patents or exclusivity periods remain that could delay certain generic entries. [1]

Source

1. DrugPatentWatch.com – Rosuvastatin patent/exclusivity tracking